ESCUDDO Long Term Follow Up
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Costa Rica1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 13,700 people, planned
- Started
- 11 Aug 2026
- Expected to end
- 15 Jan 2031
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
- Recombinant Human Papillomavirus Nonavalent Vaccine
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- TRIAL PARTICIPANTS: Participation in ESCUDDO base study
- TRIAL PARTICIPANTS: Randomization (excluding the two participants who had major protocol deviations in the ESCUDDO base study) to the Gardasil9 1- and 2-dose arms
- TRIAL PARTICIPANTS: A signed informed consent form for ESCUDDO LTFU
- TRIAL PARTICIPANTS: Opportunity to complete three total study visits
- LTFU SURVEY GROUP: We will match the current ages of ESCUDDO LTFU trial participants when they attend their 9.5-year study visit (21 to 26 years of age)
Who cannot take part
- TRIAL PARTICIPANTS: Enrollment cannot occur beyond her 10 year study visit
- LTFU SURVEY GROUP: They report they are pregnant
- LTFU SURVEY GROUP: They report being vaccinated against HPV
- LTFU SURVEY GROUP: The qualified healthcare personnel determining eligibility, in agreement with principal investigator, considers a reason that precludes participation; or
- LTFU SURVEY GROUP: They do not have an identification document
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Human papillomavirus infection or human papillomavirus-related malignant neoplasm
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
The 3 groups in the trial
- Arm I (Gardasil, Tdap)Treatment being tested
ONE DOSE GARDASIL9: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.
Treatment: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed and Recombinant Human Papillomavirus Nonavalent Vaccine
- Arm II (2 Doses Gardasil)Existing treatment, for comparison
TWO DOSE GARDASIL9: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study.
Treatment: Recombinant Human Papillomavirus Nonavalent Vaccine
- Arm III (epidemiologic survey)No study treatment, for comparison
UNVACCINATED: Participants undergo cervicovaginal and anal swab self sample collection, blood sample collection, and complete questionnaires on study. These women will be offered HPV vaccination (Gardasil9).
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")
- Criteria questions
- Built from NCT07706673, who can take part
- Record updated
- 18 November 2026